PE20091715A1 - Variantes de igf-i pegiladas y composiciones que las contienen - Google Patents
Variantes de igf-i pegiladas y composiciones que las contienenInfo
- Publication number
- PE20091715A1 PE20091715A1 PE2009000477A PE2009000477A PE20091715A1 PE 20091715 A1 PE20091715 A1 PE 20091715A1 PE 2009000477 A PE2009000477 A PE 2009000477A PE 2009000477 A PE2009000477 A PE 2009000477A PE 20091715 A1 PE20091715 A1 PE 20091715A1
- Authority
- PE
- Peru
- Prior art keywords
- igf
- variant
- sticked
- amino acids
- polyethylene glycol
- Prior art date
Links
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 title 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 208000002320 spinal muscular atrophy Diseases 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960004181 riluzole Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UNA VARIANTE DE IGF-I (FACTOR DE CRECIMIENTO SIMILAR A LA INSULINA) MODIFICADA CON POLIETILENGLICOL (PEGILADA) CARACTERIZADA PORQUE SE DERIVA DE LA SECUENCIA DE AMINOACIDOS DEL IGF-I HUMANO DE TIPO SALVAJE (SEQ ID NO: 1) Y PRESENTA UNA O DOS ALTERACIONES DE AMINOACIDOS EN LAS POSICIONES 27, 65 Y 68, DONDE EL POLIETILENGLICOL ESTA UNIDO A UN RESTO LISINA. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA QUE CONTIENE A LA VARIANTE DE IGF-I Y QUE ADICIONALMENTE, PUEDE CONTENER OTRO AGENTE ACTIVO TAL COMO RILUZOL. DICHA VARIANTE ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS NEUROMUSCULARES TALES COMO ESCLEROSIS LATERAL AMIOTROFICA (ELA), DISTROFIA MUSCULAR (DM), ATROFIA MUSCULAR ESPINAL (AME), ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08153994 | 2008-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091715A1 true PE20091715A1 (es) | 2009-11-17 |
Family
ID=41021043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000477A PE20091715A1 (es) | 2008-04-03 | 2009-04-01 | Variantes de igf-i pegiladas y composiciones que las contienen |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20090253628A1 (es) |
| EP (1) | EP2274016B1 (es) |
| JP (1) | JP5173018B2 (es) |
| KR (1) | KR101273187B1 (es) |
| CN (1) | CN101983074A (es) |
| AR (1) | AR071574A1 (es) |
| AU (1) | AU2009231394B2 (es) |
| BR (1) | BRPI0910338A2 (es) |
| CA (1) | CA2720408C (es) |
| CL (1) | CL2009000803A1 (es) |
| CR (1) | CR11692A (es) |
| EC (1) | ECSP10010516A (es) |
| ES (1) | ES2388827T3 (es) |
| IL (1) | IL208106A (es) |
| MX (1) | MX2010010495A (es) |
| PE (1) | PE20091715A1 (es) |
| RU (1) | RU2010144014A (es) |
| TW (1) | TW200944237A (es) |
| WO (1) | WO2009121759A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1674113A1 (en) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| KR101106795B1 (ko) | 2006-08-31 | 2012-01-18 | 에프. 호프만-라 로슈 아게 | 인슐린-유사 성장 인자-ｉ의 제조 방법 |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| CN101965516A (zh) * | 2008-04-03 | 2011-02-02 | 弗·哈夫曼-拉罗切有限公司 | 聚乙二醇化胰岛素样生长因子测定 |
| US20110152188A1 (en) * | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| WO2012178146A1 (en) * | 2011-06-24 | 2012-12-27 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of spinal muscular atrophy |
| CN104853778A (zh) * | 2012-10-24 | 2015-08-19 | 第一三共株式会社 | 用于肌萎缩性侧索硬化的治疗剂 |
| KR20160091888A (ko) | 2013-10-02 | 2016-08-03 | 노파르티스 아게 | 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체 |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
| EP3636670A4 (en) | 2017-05-30 | 2021-06-23 | Teijin Pharma Limited | ANTI-IGF-I RECEPTOR ANTIBODIES |
| AU2018317807A1 (en) * | 2017-08-16 | 2020-02-06 | Roxiant ApS | VTFT isoform of a BPIFB4 protein for use in neuronal diseases and injuries |
| MY205006A (en) | 2018-12-03 | 2024-09-27 | Teijin Pharma Ltd | Anti-igf-i receptor humanized antibody |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US5135956A (en) * | 1988-10-18 | 1992-08-04 | The Regents Of The University Of California | Method of using cytoprotective alcohols to treat neural disease and neural injury |
| US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
| US5158875A (en) * | 1989-08-25 | 1992-10-27 | Amgen Inc. | Production of biologically active insulin-like growth factor i from high expression host cell systems |
| NZ236819A (en) * | 1990-02-03 | 1993-07-27 | Max Planck Gesellschaft | Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions |
| US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| CA2114251C (en) * | 1991-08-01 | 2007-11-06 | Peter Gluckman | Igf-1 to improve the neural condition |
| FR2688138B1 (fr) * | 1992-03-06 | 1995-05-05 | Rhone Poulenc Rorer Sa | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique. |
| US5395822A (en) * | 1993-09-20 | 1995-03-07 | Izumi; Yukitoshi | Use of pyruvate to prevent neuronal degeneration associated with ischemia |
| JPH10500693A (ja) * | 1994-05-24 | 1998-01-20 | アムジエン・ブルダー・インコーポレーテツド | 改変型インスリン様増殖因子 |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US5906976A (en) * | 1996-10-22 | 1999-05-25 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Method and composition for treating neuronal degeneration |
| EP1141015B1 (en) * | 1999-01-06 | 2009-07-15 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| WO2000040613A1 (en) * | 1999-01-06 | 2000-07-13 | Genentech, Inc. | Insulin-like growth factor (igf) i mutant variants |
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| AR059088A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una proteina para esclerosis lateral amiotrofica |
| CL2007002502A1 (es) * | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| KR101106795B1 (ko) * | 2006-08-31 | 2012-01-18 | 에프. 호프만-라 로슈 아게 | 인슐린-유사 성장 인자-ｉ의 제조 방법 |
-
2009
- 2009-03-24 KR KR1020107021584A patent/KR101273187B1/ko not_active IP Right Cessation
- 2009-03-24 EP EP09727511A patent/EP2274016B1/en active Active
- 2009-03-24 MX MX2010010495A patent/MX2010010495A/es active IP Right Grant
- 2009-03-24 BR BRPI0910338-4A patent/BRPI0910338A2/pt not_active IP Right Cessation
- 2009-03-24 AU AU2009231394A patent/AU2009231394B2/en not_active Ceased
- 2009-03-24 ES ES09727511T patent/ES2388827T3/es active Active
- 2009-03-24 WO PCT/EP2009/053465 patent/WO2009121759A2/en active Application Filing
- 2009-03-24 JP JP2011502341A patent/JP5173018B2/ja not_active Expired - Fee Related
- 2009-03-24 CA CA2720408A patent/CA2720408C/en not_active Expired - Fee Related
- 2009-03-24 RU RU2010144014/10A patent/RU2010144014A/ru unknown
- 2009-03-24 CN CN2009801121265A patent/CN101983074A/zh active Pending
- 2009-03-26 US US12/411,673 patent/US20090253628A1/en not_active Abandoned
- 2009-04-01 TW TW098110905A patent/TW200944237A/zh unknown
- 2009-04-01 PE PE2009000477A patent/PE20091715A1/es not_active Application Discontinuation
- 2009-04-01 AR ARP090101168A patent/AR071574A1/es unknown
- 2009-04-02 CL CL2009000803A patent/CL2009000803A1/es unknown
-
2010
- 2010-09-13 IL IL208106A patent/IL208106A/en not_active IP Right Cessation
- 2010-09-27 CR CR11692A patent/CR11692A/es not_active Application Discontinuation
- 2010-10-01 EC EC2010010516A patent/ECSP10010516A/es unknown
-
2011
- 2011-04-01 US US13/078,106 patent/US20110183903A1/en not_active Abandoned
-
2013
- 2013-01-17 US US13/743,406 patent/US20140073567A1/en not_active Abandoned
-
2015
- 2015-04-13 US US14/684,772 patent/US20150273023A1/en not_active Abandoned
-
2016
- 2016-07-26 US US15/220,380 patent/US20170014488A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2720408C (en) | 2016-09-06 |
| WO2009121759A2 (en) | 2009-10-08 |
| EP2274016B1 (en) | 2012-07-25 |
| ECSP10010516A (es) | 2010-11-30 |
| JP2011518778A (ja) | 2011-06-30 |
| US20170014488A1 (en) | 2017-01-19 |
| AU2009231394A1 (en) | 2009-10-08 |
| CN101983074A (zh) | 2011-03-02 |
| US20150273023A1 (en) | 2015-10-01 |
| IL208106A (en) | 2015-09-24 |
| EP2274016A2 (en) | 2011-01-19 |
| BRPI0910338A2 (pt) | 2020-08-18 |
| MX2010010495A (es) | 2010-10-15 |
| KR20100119816A (ko) | 2010-11-10 |
| US20090253628A1 (en) | 2009-10-08 |
| CA2720408A1 (en) | 2009-10-08 |
| US20110183903A1 (en) | 2011-07-28 |
| CR11692A (es) | 2010-12-09 |
| ES2388827T3 (es) | 2012-10-19 |
| CL2009000803A1 (es) | 2010-05-07 |
| AR071574A1 (es) | 2010-06-30 |
| TW200944237A (en) | 2009-11-01 |
| JP5173018B2 (ja) | 2013-03-27 |
| WO2009121759A3 (en) | 2010-03-25 |
| AU2009231394B2 (en) | 2013-09-05 |
| IL208106A0 (en) | 2010-12-30 |
| RU2010144014A (ru) | 2012-05-27 |
| US20140073567A1 (en) | 2014-03-13 |
| KR101273187B1 (ko) | 2013-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091715A1 (es) | Variantes de igf-i pegiladas y composiciones que las contienen | |
| HRP20211415T1 (hr) | Brzodjelujući pripravci inzulina | |
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| PE20140574A1 (es) | Metodos de tratamiento de trastornos asociados con el fgf21 | |
| BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
| BR112012017054A2 (pt) | "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" | |
| PE20130511A1 (es) | Formulaciones de insulina de accion prolongada | |
| CL2008002390A1 (es) | Composicion farmaceutica que comprende una variante de fenilalanina amino-liasa de anabaena variabilis (avpal); usos contra el cancer. | |
| MX2012002861A (es) | Formulaciones farmaceuticas muy concentradas. | |
| PE20110302A1 (es) | Formulacion farmaceutica de un anticuerpo contra p-selectina | |
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| TW200733968A (en) | Stabilized lanthanum carbonate compositions | |
| MX340463B (es) | Formulaciones liquidas para un conjugado de g-csf de accion prolongada. | |
| NZ701559A (en) | Compositions comprising povidone-iodine | |
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| PL385586A1 (pl) | Nowe analogi insuliny o przedłużonym działaniu | |
| EA201490521A1 (ru) | Варианты фактора роста фибробластов 21 | |
| PE20230819A1 (es) | Composiciones y usos de glp-1 | |
| BR112014007675A2 (pt) | tratamento de doença articular degenerativa | |
| AR062775A1 (es) | Composicion farmaceutica capaz de mejorar la actividad de glp -1 en un ser humano y su uso para preparar un medicamento | |
| IN2014MN01470A (es) | ||
| PE20090387A1 (es) | Formulacion de pasireotida | |
| PE20150345A1 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo | |
| EA200900095A1 (ru) | Лекарственные формы бифосфонатов для ингаляции и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |